Immunotherapy drug shows promise in blocking oral cancer in High-Risk patients
NCT ID NCT02882282
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 21 times
Summary
This study tested whether the immunotherapy drug pembrolizumab (Keytruda) can help prevent oral cancer in 15 people with high-risk precancerous mouth lesions. Participants were randomly assigned to receive the drug or be observed. The goal was to see if the drug could keep the lesions from turning into cancer. The trial is now complete, and results help guide future prevention strategies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORAL CAVITY CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.